Investing
The company's product, Distill, uses machine learning algorithms and LLMs to perform administrative, clinical and research tasks that require chart review.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The company will use the funds to expand the reach of its sepsis-focused diagnostic test, IntelliSep.
Also, H2U has received strategic investment to take on the South Korean market.
It has also obtained its third US FDA 510(k) clearance.
Heidi Health recently raised $6.5 million in Series A funding for its nationwide expansion.
Behavioral health platform Eleos Health, virtual chronic care company Vida Health and virtual peer support company Forum also garner investment.
Also, new AI-powered mobile apps in Hong Kong support at-home stroke rehabilitation and the mental health of parents of children with special education needs.
The company also finalized its acquisition of fellow AI-powered radiology quality assurance company CoRead.
A GSR Ventures survey revealed 71% of investors believe the tech is changing their investment strategy "somewhat," and 17% say it changes their strategy "significantly."